Optimize Financial Inc Makes New $410,000 Investment in Gilead Sciences, Inc. $GILD

Optimize Financial Inc acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,691 shares of the biopharmaceutical company’s stock, valued at approximately $410,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Csenge Advisory Group boosted its position in Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares during the period. Railway Pension Investments Ltd grew its position in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC bought a new stake in Gilead Sciences during the third quarter worth approximately $1,274,000. Sector Gamma AS lifted its holdings in shares of Gilead Sciences by 15.9% in the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock valued at $16,344,000 after buying an additional 20,239 shares during the period. Finally, iA Global Asset Management Inc. boosted its position in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after purchasing an additional 23,046 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total value of $1,398,900.00. Following the completion of the transaction, the chief executive officer directly owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This trade represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 257,397 shares of company stock worth $33,385,512. 0.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Argus upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $136.73.

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ GILD opened at $146.23 on Thursday. The stock has a market cap of $181.42 billion, a PE ratio of 22.67, a PEG ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $146.73. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The business has a fifty day moving average of $126.41 and a two-hundred day moving average of $120.40.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.